Hansoh Pharma Acquires Exclusive Rights to SHR6508, a Class 1 NDA Drug from China's Leading Pharma Hengrui for Up to RMB 220 Million

Dec 29, 2025 20:30 CST Updated 20:30

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position. Authorization is required for the reprint of any article.

On the evening of December 28,Hansoh PharmaAnnouncement Release: The Company andHengrui PharmaEntering into a Licensing Agreement. According to the licensing agreement, Hansoh Pharma has obtained the exclusive license from Hengrui Pharma to operate in China.(Excluding Hong Kong, Macao and Taiwan)Development, Production and CommercializationSHR6508, and has the right to further sublicense according to the terms of the license agreement.

Source:Company Announcement

Hansoh PharmaWill pay Hengrui Pharma an upfront payment of RMB 30 million, potential regulatory and commercial milestone payments of up to RMB 190 million, and tiered royalties in the single-digit percentage of future potential net product sales.

Source: Corporate Announcement

SHR6508It is a novel calcium-sensing receptor allosteric modulator, intended for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing hemodialysis.Hyperfunction Syndrome is currently undergoing Phase III clinical trial research.The calcium-sensing receptor monitors and regulates calcium levels by releasing parathyroid hormone (PTH), which controls blood calcium levels.Due to increased sensitivity to calcium ions,SHR6508After administration, it can reduce PTH secretion in hemodialysis patients with secondary hyperparathyroidism.

Screenshot source: Global Drug R&D Database (Check Data, Find Moresun)

China is facing the challenge of an accelerating aging population, with the prevalence of chronic kidney disease on the rise. This meansSHR6508The target market has enormous potential. Hengrui Pharma's decision to license this promising project to Hansoh Pharma reflects its recognition of the value of specialized division of labor.

Screenshot source: Global Drug R&D Database (Check Data, Find Moresun)

HengRui PharmaWillSHR6508The exclusive rights for the development, production, and commercialization of the project in mainland China have been licensed to Hansoh Pharma for compensation. Hansoh Pharma mustHengrui PharmaPay the first installment of RMB 30 million.Hengrui PharmaEligible for regulatory milestone payments and commercial milestones related to the inclusion of licensed products in the National Medical Insurance Drug List.The upfront payment could be up to RMB 1.9 billion, with the right to receive tiered royalties of up to 9% based on quarterly net sales.

Hengrui PharmaAndHansoh PharmaThe related party transactions between them are not limited to the general scope of commercial cooperation., and has also built a deep-level collaborative mechanism. This cooperative model between related companies helps significantly reduce transaction costs and accelerate project progress. Based on the existing trust relationship and highly compatible corporate culture, both parties can communicate and collaborate more smoothly, thereby improving overall operational efficiency and achieving sustainable mutual benefit.

References:

Company Announcement

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Market Research Report on Anti-HIV Drugs - 202501
Market Research Report on Anti-Hepatitis Virus Drugs - 202501
Analysis of Complex Injectable Formulations Based on Dosage Form Improvement - Microspheres Section - 202501
Trends in Clinical Trials in China and the Outlook for International Multicenter Clinical Trials - 202505
Deployment Plan for AI Large Model-Based Pharmaceutical Knowledge Engineering System - 202504
Analysis Report on China's Pharmaceutical Market H2 2023-H1 2024 - April 2025
2024 National Healthcare Security Negotiation and Market Analysis Report - 202504
Top 100 List of Innovative Development of Chinese AI Medical and Health Enterprises - 202503
2024 China Class 1 New Drug Targets White Paper - 202503
More RecentlyMoxie ConsultingPopular Report, Scan the QR Code Below to Claim

Contact us to experience more professional services from Mosen Pharma.
MeetingDiscussion
CombinedWork
GardenDistrict
TakeAffairs
Database
Consultation
Customization
Service
Media
Cooperation

ClickReadRead the Original Text, apply for a free trial of Mosentropy Pharma Enterprise Edition!